OBJECTIVES The aim of this study was to identify predictors of occlusion intolerance (OI) developing during proximal protected carotid artery stenting (CAS).
with consequent transient neurological symptoms (occlusion intolerance [OI] ) (2, 4) .
The ability to predict in advance the risk of OI, which is relatively frequent (3, 4) , might help the operators to be ready to deal with this event.
Thus, the aim of the present study was to identify the predictors of developing carotid OI during proximal protected CAS. TECHNIQUE OF THE CAS PROCEDURE. All procedures were performed percutaneously with the patient under local anesthesia. At the procedure start, an 8-to 9-F, 25-cm long introducer sheath (Terumo, Tokyo, Japan) was inserted in the infrarenal aorta via the common femoral artery. After aortic arch angiography, selective bilateral carotid artery catheterization was performed using a 5-F JR4 diagnostic catheter advanced over a 0.035-inch soft hydrophilic wire (Standard Glidewire, Terumo).
METHODS
Once diagnostic angiography was completed, the wire was advanced into 1 of the ECA distal branches, the diagnostic catheter was advanced in the distal ECA, and then the hydrophilic wire was exchanged for a 300-cm, 0.035-inch stiff wire (Hi-Torque Supracore, Abbott Vascular, Abbott Park, Illinois).
The endovascular occlusion device (Mo.Ma system, Medtronic Inc., Santa Rosa, California) was guided over the stiff wire until the radiopaque marker of the distal balloon was located in the ECA, at w1 cm beyond bifurcation and in proximity to or at the superior thyroid artery (6) . Then the distal balloon CONCOMITANT THERAPY. All patients received aspirin (75 to 160 mg/day) and should have been on ticlopidine (250 mg twice daily) for at least 7 days.
Alternatively, patients received clopidogrel preload (300 mg) 24 h before the procedure. After the procedure, thienopyridines were continued for at least 3 months, whereas aspirin was continued for life. Values are mean AE SD or n (%).
CAD ¼ coronary artery disease; CVD ¼ cerebrovascular disease; COPD ¼ chronic obstructive pulmonary disease; ECA ¼ external carotid artery; ICA ¼ internal carotid artery; RAS ¼ renin-angiotensin system. Table 2) . Not surprisingly, the presence of significant pathology of the contralateral ICA was associated with higher rate of intolerance occurrence ( Table 2) .
No differences between the 2 groups were observed with respect to other cardiovascular risk factors, age, and the presence of comorbidities ( Table 2) .
Regarding procedural characteristics, patients in whom OI developed had a significantly lower OP and post-procedural blood pressure decrease ( Table 2) . Values are n (%) or mean AE SD.
Abbreviations as in Table 1 .
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Occlusion Intolerance During Proximal Protected CAS Figure 1 displays the receiveroperating characteristic curve for OP in relation to the occurrence of OI. The OP cutoff value that provided the maximal sum of the specificity and sensitivity in predicting the intolerance was #40 mm Hg. Values are mean AE SD or n (%).
Abbreviations as in Table 1 . Finally, our study suggests that the operator must pay a lot of attention to any procedural details. If the OP is #40 mm Hg, the chance of having OI is relatively high, and it will mostly occur during the phase of blood aspiration; therefore, the operator should be aware of this possibility to be ready to manage the patient's symptoms. On the other hand, if the OP is >40 mm Hg, the operator, to avoid the risk of OI, should complete the procedure within 300 s, and the systolic blood pressure should be monitored to avoid a decrease of $50 mm Hg, which can occur after stent deployment or post-dilation. In this regard, it is important to note that, in our study, the vast majority of patients experienced OI late in the procedure after stent post-dilation. This may be due to 2 important reasons: 1) as endovascular STUDY LIMITATIONS. This is a single center experience from a high volume institution with a robust experience on the use of proximal protection for CAS.
The study's finding should be confirmed in a multicenter registry before being adopted in the clinical practice.
CONCLUSIONS
Our study provides relevant information to identify those patients who can experience OI during a proximal protected CAS, an event that can be easily managed if the operator is prepared to handle it.
REPRINT REQUESTS AND CORRESPONDENCE: Dr. Eugenio Stabile, Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples "Federico II", Via Sergio Pansini 4, Naples NA 80131, Italy. E-mail: geko50@hotmail.com.
R E F E R E N C E S

